Atrial Fibrillation

2020 CCS/CHRS Guidelines

Case

You are seeing a 68 year old male in the emergency medicine department who presents with anxiety. His brother developed atrial fibrillation and he is wondering whether he should have screening. How do you counsel him and if screening is appropriate how would you do so?

Screening

Screening in Stroke

At least 24 hours of ambulatory ECG monitoring
Prolonged monitoring in select older patients if AF is still suspected

ECG

How will you workup this patient in Emerg?

Workup

CCC QoL

Know the score exists and that you would assess QoL
Important aspect of outpatient management

Case

What are risk factors for atrial fibrillation and how would you counsel the patient on modifying them?

We suggest a structured, integrated, multidisciplinary, patient-focused approach to care should be implemented for patients with AF (Weak Recommendation; Moderate-Quality Evidence).

Risk Factors

Case

You have initiated a multi-disciplinary non-pharmacologic plan for the patient and now move to the pharmacologic component. How will you manage this patient?

Rate vs Rhythm Control

I.V Procainamide

New recommendation: We suggest that a rhythm control strategy be considered for most stable patients with recent-onset AF (<1 year)
Evolving evidence, but broadly consider rhythm control in symptomatic, cannot rate control or paroxysmal. Unlikely to have to prescribe.

Anticoagulation

Note: annual reassessment
NVAF is defined as AF in the absence of mechanical heart valves or moderate to severe mitral stenosis (rheumatic or non-rheumatic)

Special Circumstances

Renal Failure

Stage 3 CKD or better (eGFR > 30 mL/min): we recommend that such patients receive antithrombotic therapy as determined by the “CCS algorithm” (YES)

Stage 4 CKD (eGFR 15-30 mL/min): we suggest that such patients receive antithrombotic therapy as determined by the “CCS algorithm” (YES)

Stage 5 CKD (eGFR < 15mL/min or dialysis dependent): we suggest that such patients not routinely receive antithrombotic therapy for stroke prevention in AF (NO)

Renal Failure

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6671778/

CAD

Dual: warfarin, apixaban 5mg, dabigatran 110/150, edoxaban 60, rivaroxaban 15

Triple: warfarin INR 2-2.5, apixaban 5, rivaroxaban 2.5 (DOAC preferred)

Duration of Triple Therapy

Interventionalist will dictate when
Balance risk of bleeding to risk of ischemic events
- patients factors, angiographic factors, ACS
Exam: discuss with Cardiology while weighing risks and benefits

Other Special Populations

Liver disease: “We recommend that OAC not be routinely prescribed in Child-Pugh class C or liver disease associated with significant coagulopathy.”
Cancer: Individualize OAC treatment in pts with active cancer. Consider DOAC> VKA.
Frail Elderly
- OAC for most frail elderly – individualizing recommendations if high risk bleed
Secondary AF (clearly provoked by a transient/reversible risk factor such as severe sepsis, thyrotoxicosis):
- No OAC:
  - Exceptions: patient’s underlying ‘abnormal substrate’ and risk for recurrence estimated to be high
    • OAC for “most patients during acute thyrotoxicosis until euthyroid state is restored”

Case

You are called to see a patient in the emergency department with rapid atrial fibrillation. He is hemodynamically stable. Emergency medicine doctors asks if it is safe to cardiovert. His CHADS65 score is 2 and the symptoms clearly started 15 hours ago. How would you proceed?